Novartis India launched Pluvicto on 15 June 2026, the first radioligand therapy in India to be approved by the drug regulator, for advanced prostate cancer
Pluvicto is lutetium (177Lu) vipivotide tetraxetan: a molecule that seeks out the PSMA protein on prostate cancer cells, joined to the radioactive isotope Lutetium-177
It is approved for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
The drug is imported from Novartis plants in Spain and Italy and will be given at select hospitals and nuclear medicine centres; India has more than 250 such centres
The US FDA first approved Pluvicto on 23 March 2022, after the phase III VISION trial showed a 38 per cent lower risk of death
A ligand is a molecule that binds to a chosen target on a cell. In RLT it is tied to a radioactive atom and injected into the blood. It attaches to the tumour's surface protein and irradiates that cell from close range.
Simple Analogy: A guided missile whose warhead is a tiny dose of radiation.
| Aspect | Radioligand therapy | External beam radiotherapy | Chemotherapy |
|---|---|---|---|
| How it is given | Injected into the bloodstream | Beamed from a machine outside the body | Injected or taken by mouth |
| What it hits | Cells carrying the target protein (PSMA here), wherever they have spread | A mapped area of the body | Fast-dividing cells, healthy ones included |
| Where it is given | Nuclear medicine centre | Radiotherapy unit | Oncology ward or day-care |
India's national drug regulator, under the Directorate General of Health Services, Ministry of Health and Family Welfare; approves new drugs and imports
Set up in 1983; regulates radiation safety, including the licensing of nuclear medicine facilities that handle radioactive drugs
Unit of the Department of Atomic Energy that produces and supplies radioisotopes and radiopharmaceuticals in India
Swiss drug maker formed in 1996 by the merger of Ciba-Geigy and Sandoz; maker of Pluvicto
The parent law for the import, manufacture and sale of medicines in India; CDSCO acts under it
Set the procedure for approving a new drug and for waiving or requiring local clinical trials
GS Paper III > Science and Technology: developments in health and nuclear applications
General Science > Radioactivity and its uses in medicine
Prostate-specific membrane antigen, a protein found in large amounts on many prostate cancer cells
Prostate cancer that has spread and keeps growing despite hormone-lowering treatment
Using one target both to image a tumour and to treat it with a radioactive drug